Document is current
Any future updates will be listed below
-
Authors
Kong, Ning
Hu, Jiankang
Liu, Dongzhou
Li, Jingyang
Wu, Huaxiang
Sun, Lingyun
Lie, Dai
Tan, Chunyu
Li, Zhijun
Xiao, Zhengyu
Huang, Cibo
Xu, Jian
Yan, Yan
Li, Hongying
Zou, Hejian
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04285229 at ClinicalTrials.govDocuments that mention this clinical trial
AB0912 IXEKIZUMAB IMPROVES SPINAL PAIN, STIFFNESS, FUNCTION, AND MOBILITY OF RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS IN CHINESE PATIENTS REGARDLESS OF BASELINE INFLAMMATION STATUS
https://doi.org/10.1136/annrheumdis-2024-eular.2412
POS0801 IXEKIZUMAB IMPROVES DISEASE ACTIVITY OF RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS IN CHINESE PATIENTS IRRESPECTIVE OF BASELINE OBJECTIVE INFLAMMATION STATUS
https://doi.org/10.1136/annrheumdis-2024-eular.357
Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level
https://doi.org/10.1007/s40744-025-00765-7
Rapid and Sustained Effect of Ixekizumab on Patient Global, Spinal Pain, Stiffness, and Fatigue in Chinese Patients with Radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-024-00688-9
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 19 November 2024
Accepted: 9 April 2025
First Online: 9 May 2025
Declarations
:
: Yan Yan and Hongying Li are employees of Eli Lilly and Company. Ning Kong, Jiankang Hu, Dongzhou Liu, Jingyang Li, Huaxiang Wu, Lingyun Sun, Dai Lie, Chunyu Tan, Zhijun Li, Zhengyu Xiao, Cibo Huang, Jian Xu, and Hejian Zou have no conflicts of interest to declare.
: The study protocol was approved by local ethics committees (Supplementary Table ) and the study was conducted in accordance with the principles outlined in the Declaration of Helsinki and the Council of International Organizations of Medical Sciences International Ethical Guidelines. All patients provided written informed consent.
